Shanghai YingLi Pharmaceutical Co. Ltd.
24
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.5% vs industry average
4%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Role: lead
A Study of AK-1286 in Patients With Advanced Solid Tumors
Role: lead
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Role: lead
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Role: lead
A Study of HY-0102 in Patients With Advanced Solid Tumors
Role: lead
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Role: lead
A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma
Role: lead
A Study of YL-17231 in Patients With Advanced Solid Tumors
Role: lead
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Role: lead
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
Role: lead
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Role: lead
A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Role: lead
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Role: lead
YL-13027 in Patients With Advanced Solid Tumors
Role: lead
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
Role: lead
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Role: lead
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
Role: lead
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Role: lead
A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Role: lead
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
Role: lead